Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Individuals affected with the neurofibromatosis 1 (NF1) tumor predisposition syndrome are prone to the development of multiple nervous system tumors, including optic pathway gliomas (OPG). The NF1 tumor suppressor gene product, neurofibromin, functions as a Ras GTPase-activating protein, and has been proposed to regulate cell growth by inhibiting Ras activity. Recent studies from our laboratory have shown that neurofibromin also regulates the mammalian target of rapamycin activity in a Ras-dependent fashion, and that the rapamycin-mediated mammalian target of rapamycin inhibition ameliorates the Nf1-/- astrocyte growth advantage. Moreover, Nf1-deficient astrocytes exhibit increased protein translation. As part of a larger effort to identify protein markers for NF1-associated astrocytomas that could be exploited for therapeutic drug design, we did an objective proteomic analysis of the cerebrospinal fluid from genetically engineered Nf1 mice with optic glioma. One of the proteins found to be increased in the cerebrospinal fluid of OPG-bearing mice was the eukaryotic initiation factor-2alpha binding protein, methionine aminopeptidase 2 (MetAP2). In this study, we show that Nf1 mouse OPGs and NF1-associated human astrocytic tumors, but not sporadic pilocytic or other low-grade astrocytomas, specifically expressed high levels of MetAP2. In addition, we show that Nf1-deficient astrocytes overexpress MetAP2 in vitro and in vivo, and that treatment with the MetAP2 inhibitor fumagillin significantly reduces Nf1-/- astrocyte proliferation in vitro. These observations suggest that MetAP2 is regulated by neurofibromin, and that MetAP2 inhibitors could be potentially employed to treat NF1-associated tumor proliferation.
Dasgupta
Biplab
B
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Yi
Yijun
Y
Hegedus
Balazs
B
Weber
Jason D
JD
Gutmann
David H
DH
D000595:Amino Acid Sequence; D000626:Aminopeptidases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000134:cerebrospinal fluid* / Q000235:genetics; D000818:Animals; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D001254:Astrocytoma / Q000134:cerebrospinal fluid / Q000150:complications / Q000201:enzymology / Q000235:genetics; D048708:Cell Growth Processes / Q000187:drug effects; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D020868:Gene Silencing; D005910:Glioma / Q000134:cerebrospinal fluid* / Q000150:complications / Q000201:enzymology / Q000235:genetics; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000134:cerebrospinal fluid / Q000235:genetics; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000134:cerebrospinal fluid* / Q000235:genetics; D063208:Methionyl Aminopeptidases; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009456:Neurofibromatosis 1 / Q000134:cerebrospinal fluid* / Q000150:complications / Q000201:enzymology / Q000235:genetics; D025542:Neurofibromin 1 / Q000172:deficiency / Q000235:genetics; D019574:Optic Nerve Neoplasms / Q000134:cerebrospinal fluid* / Q000150:complications / Q000201:enzymology / Q000235:genetics; D040901:Proteomics; D012717:Sesquiterpenes; D000077004:Tuberous Sclerosis Complex 1 Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics
D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D006023:Glycoproteins; D025542:Neurofibromin 1; D012717:Sesquiterpenes; D000077004:Tuberous Sclerosis Complex 1 Protein; D025521:Tumor Suppressor Proteins; C026211:fumagillin; D000626:Aminopeptidases; C489894:Metap2 protein, mouse; D063208:Methionyl Aminopeptidases; C106541:methionine aminopeptidase 2; D008666:Metalloendopeptidases